Brenstem Biosciences offers the best quality and cost effective Alcizin capsules for the customers as per their requirements.Alcizin comprises of Calcitriol I.P. 0.25mcg, Calcium Carbonate I.P. 500mg eq. to elemental Calcium 200mg and Magnesium oxide I.P. 50 mg. Calcitriol is the most active vitamin D3 metabolite and is produced in the kidney by vitamin D metabolite 25-hydroxyvitamin. Vit. D is the most important vitamin for the calcium absorption from the stomach and better calcium functioning in the body. Calcitriol offers fastest onset of action. It enhances Calcium absorption. In bones, calcitriol, in conjunction with parathyroid hormone, stimulates resorption of Calcium. In kidneys, it increases the tubular reabsorption of Calcium. Calcium carbonate is one of the best forms of Calcium which ensures healthy bones. It is essential for normal functioning of nerves, cells, muscle and bones. Calcium prevents bone loss and is associated with a modest reduction in fracture risk. It supplies 40% elemental calcium, compared to some other forms like Calcium gluconate which supplies only 9% of calcium. Indications: Osteoporosis in males Senile osteoporosis Steroid induced osteoporosis Pregnancy and lactation Renal osteodystrophy Fractures Vitamin D dependent rickets Renal tubular osteocalcaemia Sporadic and oncogenic hypophasphatemic osteomalacia X-linked hypophosphatemic osteomalacia Osteomalacia in Malabsorption syndrome Hypocalcaemia and hypomagnesaemia after small bowel resection Osteodystrophy Effective treatment of hypoparathyroidism during pregnancy. Management of hypocalcaemia in patients undergoing dialysis for chronic renal failure. Post-menopausal osteoporosis. Parathyroidectomy Dosage and administration: The optimal dose must be carefully determined for each patient. The recommednded intial dose is 1 capsule OD daily. If a satisfactory response in the biochemical parameters and clinical manifestations of the disease state is not observed, the dose may be increased by an increment of 1-2 capsules at 2-4 weeks interval. In patients undergoing dialysis, the dose may be increased by an increment of 1 capsule at 4-8 weeks interval. During this titration period, serum calcium and phosphorus levels should be obtained atleast twice weekly and if hypercalcemia is noted, the drug should be immediately discontinued until normocalcemia ensues. In patients undergoing dialysis, phosphorus, magnesium, alkaline phosphatase should be determined periodically. Patients should be informed of the symptoms of Hypercalcemia. Warnings and Precautions: Since calcitriol is the most potent metabolite of Vit. D available, Vit. D and its derivatives should be withheld during treatment. In patients undergoing dialysis, who have high serum phosophorus levels, appropriate serum phosphate binders should be used.